- Psychiatric Times Vol 28 No 5
- Volume 28
- Issue 5
Lorenzo’s Oil and the Rehabilitation of Gene Therapy
Gene therapy (sometimes called gene replacement therapy) attempts to ameliorate genetic-based disorders by introducing corrected genes into affected patients.
I admit to having 2 mixed responses when I rented the 1992 movie
An adenovirus carrying a corrected OT gene had been injected into Jesse’s bloodstream, with hopes of restoring this metabolic activity. Unfortunately, he mounted a catastrophic immune response to the modified adenovirus and died of multiple organ failure. A flurry of investigations ensued, the trial was halted, and the family was eventually paid an undisclosed amount of money. Having worked with gene therapy technologies early in my career, I felt this disappointment acutely.
But back to the movie, and my second mixed reaction. Lorenzo’s Oil was based on the true story of
The bad news was that the establishment initially resisted their attempts to obtain a therapeutic distillate of the oil for their child. The good news was that the parents eventually found a professional who would create the distillate. Astonishingly, the compound halted the progression of the disease (the actual Lorenzo died last year of aspiration pneumonia, having lived to an incredible age of 30 years). In this film, members of the scientific community were portrayed as churlish, narrow-minded, and subject to group-think. We can be all these things, of course-research is a very human enterprise-but coming on the same day as the report of Jesse’s death, it didn’t feel like a very good day to be a scientist.
Happily, gene therapy technologies have undergone a powerful revolution. Since Jesse’s failed trial, additional safety procedures and oversight activities have been put into play. Existing experimental protocols have been modified. Combined with technical advances in gene replacement strategies, the changes have resulted in a number of clinical success stories. One extraordinary achievement occurred this fall and involved ALD, Lorenzo’s disorder. The achievement brought back a reminder not only of the day I saw the movie but also of how far we’ve come since then. I want to tell you about what happened. I start with some background information about ALD, then move to an experiment that, at this writing, shows enormous promise.
Relevant biology
ALD is a demyelinating disease of the CNS. The mutations responsible for the disorder occur in a gene called ABCD1, which encodes an adenosine triphosphate–binding transporter protein. The protein normally hangs out in the membranes of peroxisomes of both oligodendrocytes and microglial cells. In its role as a peroxisomal transporter, it happily degrades very long-chain fatty acids in these cells. A loss of this function inhibits normal myelination maintenance by these cells.
Not surprisingly, active multifocal brain demyelination occurs in affected children, with an active degradation phase that manifests around age 6 years. Death usually occurs before puberty. It is a remarkable tribute to Lorenzo’s parents that their son lived so long.
Once there is onset of the lesion phase, it is impossible to stop the degradation, which is why therapeutic interventions are best initiated at the earliest ages possible. The only effective treatment to date is hematopoietic stem cell (HSC) therapy, classic stem cell transplantation therapy. It works by supplying replacement microglial cells derived from donor bone marrow myelomonocytic sources. There are limitations to this therapy, of course, ranging from the limited pool of compatible donors to its high fatality rate.
Gene therapy strategies
Obviously, replacing a mutated ABCD1 gene with a healthier version in affected children would be the gold standard treatment option. Since you have a brain delivery system already available with HSCs, what if you could put a corrected ABCD1 gene into those stem cells, then allow the cells to migrate via those normal pathways into the brain? What would be the first step?
Anyone contemplating gene therapy manipulations begins with the choice of molecular transport vehicles. These are normally genetically re-engineered viruses fashioned into benign vectors, each capable of delivering corrected genes to the patient.